Earnings Summary

Theravance Biopharma Inc’s revenue jumped 11.39% since last year same period to $26.15Mn in the Q2 2019. On a quarterly growth basis, Theravance Biopharma Inc has generated 389.88% jump in its revenue since last 3-months.

Theravance Biopharma Inc’s net profit jumped 2.4% since last year same period to $-39.84Mn in the Q2 2019. On a quarterly growth basis, Theravance Biopharma Inc has generated 45.11% jump in its net profits since last 3-months.

Theravance Biopharma Inc’s net profit margin jumped 12.38% since last year same period to -152.34% in the Q2 2019. On a quarterly growth basis, Theravance Biopharma Inc has generated 88.8% jump in its net profit margins since last 3-months.

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.09 - a 50% jump from last quarter’s estimates.

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.09.

Theravance Biopharma Inc’s earning per share (EPS) jumped 56.25% since last year same period to -0.21 in the Q3 2022. This indicates that the Theravance Biopharma Inc has generated 56.25% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Theravance Biopharma Inc’s return on assets (ROA) stands at -0.11.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Theravance Biopharma Inc’s return on equity (ROE) stands at -0.9.